Quick Facts
Plain-English Summary
Sermorelin is a synthetic 29-amino acid peptide corresponding to the N-terminal fragment of endogenous growth hormone-releasing hormone (GHRH 1-29). It was approved by the US FDA under the brand name Geref for the diagnosis and treatment of growth hormone deficiency in children, and later for adult GH assessment. Serono (now EMD Serono) discontinued the product in 2008 for commercial reasons — the approval of long-acting recombinant HGH products made Geref economically unviable — not due to safety or efficacy concerns.
Sermorelin is now widely compounded by licenced pharmacies in the US and prescribed off-label for adult GH optimisation. Its clinical history and regulatory background give it the strongest evidence and safety profile of any compounded GHRH analogue.
Sermorelin's FDA approval history distinguishes it from all other compounded GHRH analogues. The compound was commercially withdrawn — not recalled or pulled for safety reasons — a distinction that materially affects its risk profile interpretation.
Unlike synthetic analogues such as CJC-1295 or Mod GRF 1-29, Sermorelin's short half-life (~10–20 minutes) means it produces pulse-based GH stimulation that mirrors the body's natural secretion pattern. Somatostatin feedback regulation remains intact, which limits the risk of GH axis suppression associated with continuous stimulation.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rodent GH/IGF-1 elevation | Dose-dependent increases in GH pulse amplitude and IGF-1 plasma levels demonstrated consistently across rodent models. Effect magnitude correlates with Sermorelin dose and injection timing relative to endogenous GH pulses. | Preclinical |
| Lean mass & body composition | Rodent studies demonstrate increased lean body mass and reduced adiposity with repeated Sermorelin dosing. Effects are consistent with GH-mediated anabolic signalling and IGF-1 elevation. | Preclinical |
| Bone mineral density | Sustained Sermorelin administration associated with improved bone mineral density in rodent models. GH and IGF-1 are established mediators of bone remodelling and osteoblast activity. | Preclinical |
| Wound healing | Enhanced wound healing rates observed in rodent models, consistent with GH-stimulated IGF-1 and the known role of GH axis activation in tissue repair and cellular proliferation. | Preclinical |
| Primate pharmacodynamics | Non-human primate studies support the human clinical pharmacodynamic findings. GH pulse augmentation and IGF-1 response confirm translational relevance of rodent data for GHRH receptor pharmacology. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| FDA-approved paediatric GH deficiency (Geref) | Children with GH deficiency; RCT design; primary endpoint height velocity | — | Approved Data |
| Adult GH pulse augmentation | Healthy elderly men; single nightly injections; GH pulse and IGF-1 endpoints | — | Completed |
| Adult GH insufficiency (Geref diagnostic use) | Adults with suspected GH insufficiency; stimulation test protocol | — | Approved Data |
| Body composition, sleep & energy (off-label) | Adults; qualitative outcomes assessed in smaller adult studies | — | Limited |
Sermorelin has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Sermorelin has the best-documented safety profile of any compounded GH secretagogue given its regulatory history. No serious systemic adverse events attributable to Sermorelin were identified during its 18-year FDA-approved commercial lifespan.
Documented in clinical trials and post-marketing surveillance: injection site reactions (erythema, swelling), flushing, and headache. These effects are generally mild and transient. Documented in controlled trials, not solely from self-reported community data.
- IGF-1 monitoring during long-term use advisable
- Fasting glucose and metabolic parameters
- Thyroid function (GH axis interactions)
- Annual bloodwork recommended for off-label adult use
- Dose titration guided by IGF-1 response
- Active or suspected malignancy
- Pregnancy or breastfeeding
- Diabetic retinopathy or proliferative conditions
- Uncontrolled hypothyroidism
- Children and adolescents (outside supervised clinical care)
Sermorelin is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Sermorelin for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
3 years on compounded Sermorelin prescribed by my anti-ageing physician. IGF-1 maintained in optimal range. Sleep quality improved substantially. Annual bloodwork all normal. This is the peptide I'd recommend to anyone wanting to start with something that has real regulatory history behind it.
Same experience. The fact that it was FDA approved, compoundable, and has a 30-year safety record is what makes it the rational choice over unregulated analogues.
Sermorelin's FDA history is often misunderstood. It was withdrawn commercially, not recalled for safety. That's an important distinction that gives it a fundamentally different risk profile than peptides that have never been near a regulatory agency.
The practical difference between Sermorelin and Mod GRF 1-29 is DPP-IV resistance. Mod GRF lasts longer because of the amino acid substitutions. For the same mechanism with more stability, Mod GRF is the research choice. For the legal/prescription route, Sermorelin is the answer.
Exactly right. Same receptor, different half-lives. Pick based on your context — prescription vs research.
Worth noting for historical context: Sermorelin (Geref) was approved by FDA in 1990, used clinically for 18 years, then discontinued when recombinant HGH captured the market. The pharmacological data accumulated over those 18 years is a meaningful evidence base.